Fresenius Medical Care AG (FMS) Financial Statements

Executive TeamFinancials
Shareholders

Fresenius Medical Care financial statements at a glance

Fresenius Medical Care reported revenue of 19.63 billion EUR for fiscal year 2025 (ended December 31, 2025), up 1.5% from fiscal year 2024. Net income was 978.37 million EUR, a net margin of 5.0%, and diluted earnings per share were 1.68 EUR.

At the end of fiscal year 2025 it had total assets of 31.00 billion EUR, total liabilities of 16.72 billion EUR and shareholders' equity of 13.31 billion EUR, with cash and short-term investments of 1.82 billion EUR and total debt of 10.80 billion EUR.

Its operations brought in 2.68 billion EUR of cash; capital spending was 915.37 million EUR, leaving free cash flow of 1.77 billion EUR.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in EUR; latest fiscal year ended December 31, 2025.

FMS logo

Fresenius Medical Care AG

FMSGermany
Healthcare
EUR (Local)

Income Statement

Annual • EUR

Total Revenue
19.63B
Prev Year: 19.34B
YoY: +1.5%
Operating Revenue
19.63B
Prev Year: 19.34B
YoY: +1.5%
Normalized EBITDA
3.58B
Prev Year: 3.42B
YoY: +4.7%
Tax Rate for Calcs
0.212
Prev Year: 0.299
YoY: -29.1%
Tax Effect of Unusual Items
-38.41M
Prev Year: -62.75M
YoY: +38.8%
Total Unusual Items
-181.16M
Prev Year: -209.86M
YoY: +13.7%
Total Unusual Items Excluding Goodwill
-181.16M
Prev Year: -209.86M
YoY: +13.7%
Other Income Expense
212.0K
Prev Year: -74.98M
YoY: +100.3%
Special Income Charges
-60.32M
Prev Year: -230.83M
YoY: +73.9%
Gain on Sale of Property, Plant and Equipment
993.0K
Prev Year: 14.66M
YoY: -93.2%
Gain on Sale of Business
-61.32M
Prev Year: -245.49M
YoY: +75.0%
Equity in Earnings of Affiliates
181.37M
Prev Year: 134.88M
YoY: +34.5%
Gain on Sale of Securities
-120.83M
Prev Year: 20.97M
YoY: -676.2%
Other General and Administrative
2.41B
Prev Year: 2.37B
YoY: +2.0%
Cost of Revenue
14.60B
Prev Year: 14.58B
YoY: +0.1%
Gross Profit
5.03B
Prev Year: 4.76B
YoY: +5.7%
Operating Expense
3.20B
Prev Year: 3.29B
YoY: -2.7%
Selling General and Administrative
3.03B
Prev Year: 3.14B
YoY: -3.5%
General and Administrative Expense
2.41B
Prev Year: 2.37B
YoY: +2.0%
Selling and Marketing Expense
618.14M
Prev Year: 776.53M
YoY: -20.4%
Research and Development
157.97M
Prev Year: 183.49M
YoY: -13.9%
Other Operating Expenses
11.40M
Prev Year: -37.04M
YoY: +130.8%
Operating Income
1.83B
Prev Year: 1.47B
YoY: +24.5%
Net Non Operating Interest Income Expense
-314.80M
Prev Year: -335.47M
YoY: +6.2%
Non-operating Interest Income
69.61M
Prev Year: 71.58M
YoY: -2.7%
Non-operating Interest Expense
384.41M
Prev Year: 407.04M
YoY: -5.6%
Pre-tax Income
1.51B
Prev Year: 1.06B
YoY: +43.1%
Provision for Income Taxes
320.97M
Prev Year: 316.06M
YoY: +1.6%
Net Income Common Stockholders
978.37M
Prev Year: 537.91M
YoY: +81.9%
Net Income
978.37M
Prev Year: 537.91M
YoY: +81.9%
Net Income Including Non-Controlling Interests
1.19B
Prev Year: 740.87M
YoY: +60.8%
Net Income from Continuing Operations
1.19B
Prev Year: 740.87M
YoY: +60.8%
Noncontrolling Interests
-212.90M
Prev Year: -202.96M
YoY: -4.9%
Diluted NI Available to Com Stockholders
978.37M
Prev Year: 537.91M
YoY: +81.9%
Basic EPS
1.68
Prev Year: 0.915
YoY: +83.6%
Diluted EPS
1.68
Prev Year: 0.915
YoY: +83.6%
Weighted Average Shares (basic)
582.38M
Prev Year: 586.83M
YoY: -0.8%
Weighted Average Shares (diluted)
582.38M
Prev Year: 586.83M
YoY: -0.8%
Total Operating Income as Reported
1.83B
Prev Year: 1.39B
YoY: +31.2%
Total Expenses
17.80B
Prev Year: 17.87B
YoY: -0.4%
Net Income from Continuing and Discontinued Operation
978.37M
Prev Year: 537.91M
YoY: +81.9%
Normalized Income
1.12B
Prev Year: 685.02M
YoY: +63.7%
Interest Income
69.61M
Prev Year: 71.58M
YoY: -2.7%
Interest Expense
384.41M
Prev Year: 407.04M
YoY: -5.6%
Net Interest Income
-314.80M
Prev Year: -335.47M
YoY: +6.2%
EBIT
1.90B
Prev Year: 1.46B
YoY: +29.6%
EBITDA
3.40B
Prev Year: 3.21B
YoY: +6.0%
Reconciled Cost of Revenue
14.60B
Prev Year: 14.58B
YoY: +0.1%
Reconciled Depreciation
1.50B
Prev Year: 1.74B
YoY: -13.9%
Net Income from Continuing Operation Net Minority Interest
978.37M
Prev Year: 537.91M
YoY: +81.9%
Values in EUR

Fresenius Medical Care key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue19.6B EUR19.3B EUR19.5B EUR19.4B EUR17.6B EUR
Gross profit5.0B EUR4.8B EUR4.9B EUR4.9B EUR4.8B EUR
Operating income1.8B EUR1.5B EUR1.5B EUR1.5B EUR1.9B EUR
Net income978.4M EUR537.9M EUR499.0M EUR673.4M EUR969.3M EUR
Diluted EPS1.68 EUR0.92 EUR0.85 EUR1.15 EUR1.66 EUR
Total assets31.0B EUR33.6B EUR33.9B EUR35.8B EUR34.4B EUR
Total liabilities16.7B EUR17.8B EUR19.1B EUR20.3B EUR20.4B EUR
Shareholders' equity13.3B EUR14.6B EUR13.6B EUR14.0B EUR12.7B EUR
Cash and short-term investments1.8B EUR1.4B EUR1.5B EUR1.4B EUR1.6B EUR
Total debt10.8B EUR11.0B EUR12.1B EUR13.2B EUR13.3B EUR
Operating cash flow2.7B EUR2.4B EUR2.6B EUR2.2B EUR2.5B EUR
Capital spending915.4M EUR699.4M EUR684.6M EUR724.0M EUR854.4M EUR
Free cash flow1.8B EUR1.7B EUR1.9B EUR1.4B EUR1.6B EUR

In EUR. Fiscal years as reported by the company; statements on this page go back to fiscal year 2020.

Questions and answers

What was Fresenius Medical Care's revenue in fiscal year 2025?

19.63 billion EUR, up 1.5% from 19.34 billion EUR in fiscal year 2024.

How much profit does Fresenius Medical Care make?

Fresenius Medical Care reported net income of 978.37 million EUR for fiscal year 2025 (5.0% of revenue); operating income was 1.83 billion EUR.

How much cash and debt does Fresenius Medical Care have?

At the end of fiscal year 2025: cash and short-term investments of 1.82 billion EUR and total debt of 10.80 billion EUR.

What is Fresenius Medical Care's free cash flow?

1.77 billion EUR in fiscal year 2025 (operating cash flow of 2.68 billion EUR minus capital spending of 915.37 million EUR).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube